 |
PUBLICATIONS
JOURNAL ARTICLES
Free Access to abstracts at PubMed
- Geller M,Eisenberger MA. Consideracoes
gerais sobre cardiopatias congenitas. A Folha Medica 62(4):
419-432, 1971.
- Tejada F, Eisenberger M, Broder L, Cohen
M, and Simon R. 5-Fluorouracil versus CCNU in the treatment of metastatic
prostatic cancer. Cancer Treat Reports 6:1589-1590, 1977.
- Denefrio J, Kaplan R, Eisenberger M,
and Lessner HE. Phase II study of cyclophosphamide and cytarabine
in the treatment of adenocarcinoma of the colon and rectum. Cancer
Treat Reports 65:163-164, 1980.
- Eisenberger M. The role of chemotherapy
in the treatment of head and neck cancer. Miami Medicine
1:23, 1980.
- Eisenberger M, Denefrio J, Silverman
M, and Lessner H. Combination chemotherapy with bleomycin and hydroxyurea
in the treatment of advanced head and neck cancer. Cancer Treat
Rep 66:1438-1440, 1982.
- Warner B, Worgul T, Drago, J, Demers L, Dufau M, Hay D, Santen
R, and Members of the Abbot Study Group. Effects of very high dose
D-leucine 6-gonadotropin-releasing hormone proethylamide on the
hypothalamic-pituitary testicular axis in patients with prostatic
cancer. Journal Clinical Invest 71:1842-1853, 1983. (Major
Input in Patient Accrual and Active Participant in Study).
- Eisenberger M. Combination chemotherapy
with bleomycin and hydroxyurea in the treatment of advanced head
and neck cancer. O.R.I. Digest 4-5, 1983.
- Leuprolide Study Group. Leuprolide versus diethylstilbestrol
for metastatic prostate cancer. NEJM 311:1281-1286, 1984. (Participated
in the preparation of the manuscript and accrued over 10% of the
patients reported).
- Eisenberger M, Simon R, O'Dwyer P, Wittes
R, and Friedman M. A re-evaluation of non-hormonal cytotoxic chemotherapy
in the treatment of prostatic cancer. J Clin Oncol 3:827-841,
1985.
- Eisenberger M. Supporting evidence for
an effective treatment program for salivary gland tumors. Cancer
Treat Reports 69:319-321, 1985.
- Krasnow W, Patterson D, Fishman B, Eisenberger M,
Johnston-Early A, Citron M, and Cohen M. Local toxicity from intravenous
Baker's Antifol. Cancer Treat Reports 65:735-736, 1985.
- O'Dwyer P, Leyland-Jones B, Alonso M, Eisenberger M, and Hoth D. Dichloromethotrexate - A critical reassessment.
J Clin Oncol 3:1148-1153, 1985.
- Ellenberg S, and Eisenberger M. An efficient
design for phase II studies of combination chemotherapies. Cancer
Treat Reports 1147-1152, 1985.
- Smith J (for Leuprolide Study Group). Clinical effects of gonadotropin-releasing
hormone analogue in metastatic carcinoma of prostate. Urology
25:106-114, 1985 (Member of the Leuprolide Study Group).
- Eisenberger M, O’Dwyer P, Friedman
M. Gonadotropin hormone-releasing hormone analogues: a new therapeutic
approach for prostatic carcinoma. J Clin Onc 4:414-424,
1986.
- Eisenberger M, Hornedo J, Silva J, Donehower
R, Spaulding M, and Van Echo D. Carboplatin (NSC-241-240): An active
platinum analog for the treatment of squamous cell carcinoma of
the head and neck. J Clin Oncol 4:1506-1509, 1986.
- Krasnow S, Green M, Perry D,Eisenberger M,
Johnson-Early A, Muggia F, and Cohen M. Phase II trial of Baker's
antifol in patients with recurrent or inoperable head and neck cancer.
Cancer Treat Rep 70:1039-1040, 1986.
- Vogel CL, Gorowski E, Davila E, Eisenberger M,
Kosinski J, Agonwal R, and Savaroj N. Phase I clinical trial and
pharmacokinetics of weekly ICRF-187 (NSC 169 780) infusion in patients
with solid tumors. Investigational New Drugs 5:187-198,
1987.
- Tchekmedyian N, Kaplan R, Eisenberger M,
Abrams J, and Van Echo D. Phase II study of Nmethylformamide (NMF)
in patients with advanced colorectal cancer. Cancer Treat Rep
71:541-542, 1987.
- Eisenberger M, Kennedy P, and Abrams
J. Cytotoxic chemotherapy for disseminated prostatic cancer. Oncology
4:4:59-69, 1987.
- Belani C, Eisenberger M, Van Echo D,
Hiponia D, and Aisner J. A phase II study of caracemide in advanced
or recurrent non-small cell lung cancer. Cancer Treat Rep
71:1099-1100, 1987.
- Conley B, Hornedo J, Abrams J,Eisenberger M,
Hiponia D, Aisner J, and Van Echo D. A phase II trial of 4'-deoxydoxorubicin
in advanced non-small cell lung cancer. 71:861-862, 1987.
- Eisenberger M, Bezerdjian L, and Kalash
S. A Critical evaluation of non-hormonal cytotoxic chemotherapy
for advanced prostatic cancer. Urological Clinics of North America.
Donnoghue J (ed) 14(4): 695-706, 1987.
- Eisenberger M. Controversies involving
the systemic treatment for metastatic prostatic cancer. Rev
Bras Cancerol 33:39-49, 1987.
- Chodak GW, Eisenberger MA, Scardino PT,
Torit FM. Detecting prostate cancer early. Patient Care
21(7): 69-73, 1987.
- Chodak GW, Eisenberger MA, Scardino PT,
Torti FM. Current management for prostate cancer. Patient Care
21(7): 74-93, 1987.
- Chodak G, Eisenberger M, Scardino P,
and Torti F. Diagnosis and treatment of prostatic cancer. Patient
Care 25:69-93, 1987.
- Eisenberger M, and Abrams J. Gonadotropin hormone
releasing hormone for the treatment of prostatic cancer. Drugs of
Today, J.R. Rpis (ed), Barcelona, Spain, 24:241-248, 1988.
- Eisenberger M, Jacobs M, Drake K, Bajaj K, Kennedy
P, Elias G, and Gray W. Simultaneous treatment with carboplatin
(CBDCA) and conventional radiotherapy for unresectable loco-regional
squamous cell carcinoma of the head and neck, Phase I-II study.
Head and Neck Oncology Research 1:431-436, 1988.
- Eisenberger M, and Abrams JS. Chemotherapy for
prostatic cancer. Sem in Urology VI (4): 303-310, 1988.
- Eisenberger M, Bezirdjian L, and Kalash S. A critical
assessment of the role of chemotherapy for endocrine resistant prostatic
carcinoma. American Urological Update Series, Lesson 28,
Volume VII: 218-224, 1988.
- Eisenberger M, Ellenberg S, Leyland-Jones B, and
Friedman M. The application of a two-step design clinical trials
in patients with recurrent head and neck cancer. Med Ped Oncol
16:162-168, 1988.
- Belani C, Eisenberger M, and Gray W. Preliminary
experience with combination chemotherapy in the treatment of advanced
neoplasms of the salivary glands. Med Ped Oncology 16:197-202,
1988.
- Eisenberger M. Chemotherapy for prostatic cancer.
In: NIH Consensus Development Conference on the Treatment of Prostate
Cancer, NCI monograph 7:151-163, 1988.
- Eisenberger M, Jacobs M, Sinibaldi V, and Gray
W. Simultaneous treatment with CBDCA (NSC 241-240) and radiotherapy
in advanced unresectable squamous cell carcinomas of the head and
neck. Cancer Treat Rev 15(B):3-7, 1988.
- Nanus D, Kelsen D, Lipperman R, and Eisenberger M.
Phase-II trial of ifosfamide in epidermoid carcinoma of the esophagus:
unexpectant severe toxicity. Investigational New Drugs
6:239-241, 1988.
- Crawford E, McLeod D, Dorr A, Spaulding J, Benson R, Eisenberger M, Blumenstein B. A Comparison of leuprolide with flutamide
and leuprolide in untreated stage D2 prostate cancer. Endocrinology
2:63, 1988.
- Eisenberger M, Van Echo D, Aisner J. Carboplatin
the experience in head and neck cancer. Seminars in Oncology
16(21): 5:34-41, 1989.
- Jacobs M, Eisenberger M, Oh MC, Sinibaldi V, Gray
W, Elias G, and Salazar O. Carboplatin and radiation for stage IV
carcinoma of the head and neck: A phase I-II study. Int J Radiation
Oncology Biol Phys 17: 361-363, 1989.
- Crawford E, Eisenberger M, Benson R, McLeod D,
Dorr A, Spaulding S, Blumenstein B, Davis M, and Goodman P. A controlled
trial of leuprolide with and without flutamide in prostatic carcinoma.
NEJM 321:419-424, 1989.
- Eisenberger M, Krasnow S, Ellenberg S, Sinibaldi
V, Silva H, Abrams J, Van Echo D, and Aisner J. A comparison of
carboplatin and methotrexate versus methotrexate alone in recurrent
head and neck cancer. J Clin Oncol 7:1341-1345, 1989.
- Abrams J, Tait N, Silva H, Eisenberger M, Van Echo
D, Oliver I, and Aisner J. Phase II trial of N-methylformamide in
advanced renal cancer. Am J Clin Oncol (CCT) 12:41-42,
1989.
- Belani C, Egorin M, Abrams J, Hiponia D, Eisenberger M,
Aisner J, Van Echo D. A novel pharmacodynamically based approach
to dose optimization of carboplatin when used in combination with
etoposide. J Clin Oncol 7:1896-1902, 1989.
- Ginn D, Kelsen D, Eisenberger M, Heelan R, and
Magill G. Phase II trial of carboplatin and vinblastine in adenocarcinoma
of the stomach. Investigational New Drugs 8:321-324, 1990.
- Eisenberger M. The management of endocrine resistant
prostate cancer. World J Urol 8:40-46, 1990.
- Scher H, Smart Curley J, Geller N, and Eisenberger M.
Trimetrexate in prostatic cancer: preliminary observations on the
use of prostate-specific antigen and acid phosphatase as a marker
in measurable hormone-refractory disease. J Clin Oncol
1830-1838, 1990.
- Abrams J, Rayner A, Wiernik P, Parkinson D, Eisenberger M, and Hawkins M. High dose recombinant interleukin-2 alone:
a regimen with limited activity in the treatment of advanced renal
cell cancer. J Natl Cancer Inst. 82:1202-1206, 1990.
- Crawford E, Blumenstein B, Goodman P, Davis M, Eisenberger M, McLeod D, Spaulding J, Benson R, and Dorr A. Leuprolide
with and without flutamide for advanced prostate cancer. Cancer
66:1039-1044, 1990.
- Von Hoff D, Blumenstein B, Pollock T, Crawford E, Eisenberger M et al. Phase II study of methyl-glioxal bis-guanylhydrazone
(MGBG) in patients with advanced bladder cancer. European Journal
of Cancer 26: 848-849, 1990.
- Lovett D, Kelsen D, Eisenberger M, and Houston C.
A Phase II trial of carboplatin and vinblastine in the treatment
of advanced squamous cell carcinoma of the esophagus. Cancer
67:354-356, 1991.
- Crawford E, Eisenberger M, McLeod D, et al. A comparison
of leuprolide - with and without flutamide - in previously untreated
patients with disseminated prostate carcinoma. Exerpta Medica
N. 477, 1991.
- Kruter F, Eisenberger M, Sinibaldi V, Jacobs M,
and Gray W. Continuous infusion IV 6-thioguanine for patients with
recurrent and metastatic squamous cell carcinoma of the head and
neck. Invest New Drugs 10: 89-91, 1991.
- McLeod D, Crawford E.D, Blumenstein B, Eisenberger M,
Dorr F.A. Controversies in the treatment of metastatic prostate
cancer. Cancer 70:324-328, 1991.
- Eisenberger M. Chemotherapy for carcinomas of the
penis and urethra. Urological Clinics of North America
19:333-338, 1992.
- Eisenberger M, and Jacobs M. Simultaneous treatment
with single agent chemotherapy and radiation therapy for locally
advanced cancer of the head and neck. Seminars in Oncology 19
(Suppl 11):41-46, 1992.
- Gregory L, Eisenberger M, and Sinibaldi V. Analytical
interference associated with suramin administration. Clinical
Chemistry 38: 2552-2553, 1992.
- Eisenberger M, Reyno L, Jodrell D, Sinibaldi V,
Tkaczuk K, Sridhara R, Zuhowski E, Louis M, Jordon SC, and Egorin
MJ. Suramin, An active drug for prostate cancer: Interim observation
in a phase I trial. JNCI 85:611-621, 1993.
- McLeod D, Benson R, Eisenberger M, Crawford E,
Blumenstein B, Spicer D, and Spaulding J. The use of flutamide in
hormone-refractory metastatic prostate cancer. Cancer (Suppl.)
75:3870-3873, 1993.
- Marshall M, Wolf M, Crawford E, Taylor S, Blumenstein B, Flanigan
R, Meyers F, Hynes H, Barlogie B, and Eisenberger M.
Phase-II trial of echinomycin for the treatment of advanced renal
cell carcinoma. Investigational new Drugs 11:207-209, 1993.
- Marshall EM, Blumenstein B, Crawford E, Thompson I, Craig J,
Eisenberger M, and Ahman F. Phase II trial of Amonafide
for the treatment of hormonally refractory carcinomas of the prostate:
A Southwest Oncology Group Study. Am J Clin Oncol 17:514-515,
1994.
- Jodrell D, Reyno L, Sridhara R. Eisenberger MA,
Tkaczuk K, Zuhowski E, Sinibaldi V, Novak M, and Egorin M. Suramin:
Development of a population pharmacokinetic model and its use with
intermittent short infusions to control plasma drug concentration
in patients with prostate cancer. J. Clin Oncol 12:166,
1994.
- Hussain M, Wolf M, Marshall E, Crawford E, and Eisenberger M. Effects of continued androgen deprivation therapy and
other prognostic factors on response and survival in phase-II chemotherapy
trials for hormone-refractory prostate cancer: A Southwest Oncology
Group Report, J Clin Oncol 12:1868-1875, Sept.1994.
- Eisenberger M and Reyno L. New Drugs: Suramin.
Cancer Treat Rev: 259-273, 1994.
- Eisenberger M, Crawford E, Wolf M, Blumenstein
B, McLeod D, Benson R, Dorr F, Benson M, and Spaulding J. Prognostic
factors in stage D2 prostate cancer; important implications for
future trials: Results of a cooperative intergroup study (INT. 0036).
Seminars in Oncology 21:613-619, 1994.
- De Antoni E, Crawford E, Stone N, Blum D, Berger R, Eisenberger M, Gambert S, and Staggers F. Prostate Cancer Awareness
Week, 1992: A summary of key findings. Clin Invest Med
16:448-457, 1994.
- Marshall M, Blumenstein B, Crawford E, Win Q, Miller T, Meyers
F, Wolfe M, Eisenberger M, and Einstein A. A phase
II study of CHIP for the treatment of hormonally refractory carcinoma
of the prostate: A Southwest Oncology Group Study. American
Journal of Clin Oncol 18:400-402, 1995.
- Jacobs M, Suntharalingam M, Eisenberger M, Sinibaldi
V, and Salazar O. Combined carboplatin + bleomycin and conventional
radiotherapy for advanced head and neck cancer. Amer J Clin
Onc 18:1, 52-55, 1995.
- Crawford E, Hussain M, DeAntoni E, Thompson I, Eisenberger M, Blumenstein B, and Coltman C. Southwest Oncology Group
Strategies in Prostatic Carcinoma: Seminars in Surgical Oncology.
11:60-64, 1995.
- Williamson S, Wolf M, Eisenberger M, O'Rourke M,
Brannon W, and Crawford ED. Phase II evaluation of didemnin b in
hormonally refractory metastatic prostate cancer. A Southwest Oncology
Group Study. Invest New Drugs 13:167-170, 1995.
- Twillie D, Eisenberger M, Carducci M, Hseih W-S,
Kim W, and Simons J. Interleukin-6: a candidate mediator of human
prostate cancer morbidity. Urology 45:542-549, 1995.
- Eisenberger M, Sinibaldi V, and Reyno L. Suramin:
Cancer Practice 3:187-189, 1995.Sridhara R, Eisenberger M,
Sinibaldi V, Reyno L, and Egorin M. Evaluation of prostate specific
antigen as a surrogate marker for prostate cancer. J Clin Oncol
13:2944-2953, 1995.
- Eisenberger M, Sinibaldi V, Reyno L, Sridhara R,
Jodrell DI, Zuhowski E, Tkaczuk K, Lowitt M, Hemady RK, Jacobs SC,
Van Echo D, and Egorin M. Phase I and clinical evaluation of a pharmacologically
guided regimen of suramin in patients with hormone-refractory prostate
cancer. J Clin Oncol 13:2174-2186, 1995.
- Reyno L, Egorin M, Eisenberger M, Sinibaldi V,
Zuhowski E, and Sridhara R. Development and validation of a pharmacokinetically
based, fixed dosing schema of suramin. J Clin Oncol 13:2187-2195,
1995.
- Nelson J, Hedican S, George D, Reddi, A.H., Piantadosi S, Eisenberger M, and Simons J. Identification of endothelin-1 in the pathophysiology
of metastatic adenocarcinoma of the prostate. Nature Med 1:944-949,
1995.
- Prostate Cancer Trialists’ Collaborative Group. Maximum
androgen blockade in advanced prostate cancer: an overview of 22
randomized trials with 3283 deaths in 5710 patients. The Lancet
346:265-269, 1995.
- Lowitt M, Eisenberger M, Sina B, and Kao G. Cutaneous
eruptions from suramin: a clinical and histopathologic study of
60 patients. Arch Dermatol 131:1147-1153, 1995.
- Eisenberger M, Reyno L, Sinibaldi V, Sridhara R,
Carducci M, and Egorin M. The experience with suramin in advanced
prostate cancer. Cancer 75:1927-1934, 1995.
- Williamson S, Wolf M, Eisenberger M, O'Rourke M,
Brannon W, and Crawford E. Phase II evaluation of ifosfamide/mesna
in metastatic prostate cancer. A Southwest Oncology Group Study.
Amer J of Clin Onc (CCT) 19(4):368-370, 1996.
- Eisenberger M, Sinibaldi V, Reyno L, Sridhara R,
Jacobs S, and Egorin M. Active and safe schedule developed for outpatient
use of suramin. AUA Today 9:1, 1996.
- Hemady R, Sinibaldi V, and Eisenberger M. Ocular
symptoms and signs associated with suramin sodium treatment for
metastatic cancer of the prostate. Amer Jour Opthalmology 121:291-296,
1996.
- Crawford E, DeAntoni E, Etzioni R, Schaefer V, Olson R, Ross
C, and Eisenberger M. Serum prostate-specific antigen
and digital rectal examination for the early detection of prostate
cancer in a national community-based program. Urology 14:863-869,
1996.
- Chaudhry V, Eisenberger M, Sinibaldi V, Sheikh
K, Griffin J, and Cornblath D. A prospective study of suramin-induced
peripheral neuropathy. Brain 119:2039-2052, 1996.
- Eisenberger M and Nelson W. How much can we rely
on psa as an endpoint for evaluation of clinical trials? A word
of caution! JNCI 88(12):779-781, 1996.
- Hussain M, Blumenstein B, Eisenberger M, and Crawford
E.D. Southwest Oncology Group Studies in Hormone Refractory Prostate
Cancer. Sem in Onc 23(14):24-27, 1996.
- Carducci M, DeWeese T, Nelson W, Simons J, Sinibaldi V, and Eisenberger M. Prostate cancer treatment strategies based on tumor-specific
biological principles: the Johns Hopkins approach. Sem in Onc
23(14):56-62, 1996.
- Newling D, Fossa S, Andersson L, Per-Anders A, Yoshio A, Eisenberger M, Khoury S, Kozlowski J, Kelly K, Scher H, Hartley-Asp
B. Assessment of hormone refractory prostate cancer. Urology
49(4a):46-53, Suppl April 1997.
- Eisenberger M, Sinibaldi V, Reyno L, Sridhara R,
Jodrell D, Zuhowski E, Tkaczuk K, Lowitt M, Hemady R, Stephen J,
VanEcho D and Egorin M. Phase I and Clinical Evaluation of a Pharmacologically
Guided Regimen of Suramin in Patients With Hormone-Refractory Prostate
Cancer. Classic Papers and Current Comments, Vol 2 (No
2) 1997:345-357.
- Eisenberger M. Submitted to Oncology by invitation
- Commentary on an article entitled A Management of progressive
metastatic prostate cancer.@ Oncology 11(10): 1560-1561,
1997.
- Sridhara R, Eisenberger M, Sinibaldi V, Reyno L,
Egorin M. Evaluation of Biomarkers of Survival response in Hormone-Refractory
Prostate Cancer Patients Treated with Suramin. Cancer Epidemiology,
Biomarkers, Vol 7, 631-634, July 1998.
- Moinpour C, Savage M, Troxel A, Lovato L, Eisenberger M,
Veith R, Higgins B, Skeel R, Yee M, Blumenstein B, Crawford D, Meyskens
F. Quality of Life In Advanced Prostate Cancer: Results of a Randomized
Therapeutic Trial. J Natl Cancer Inst 90:1537-44, 1998.
- Eisenberger M, Blumenstein B, Crawford E, McLeod
D, Loehrer p, Wilding G, Sears K, Culkin D, Thompson I, Bueshen
A, Lowe B. A Randomized and Double-Blind Comparison of Bilateral
Orchiectomy with or without Flutamide for the Treatment of Patients
with Stage D2 Prostate Cancer: Results of NCI Intergroup 0105.
N ENG J Med 339:1036-42, 1998.
- Sridhara R, Eisenberger M, Reyno LM, Jodrell DI,
Sinibaldi V, Zuhowski EG, Egorin MJ. Comparison of Iterative-Two
Stage and Bootstrap Sampling Approaches in the Development of a
Population Pharmacokinetic Model. International Federation of
Automatic Control pp 141-145, March 1998.
- Eisenberger, MA. Modulation of Growth Factors Action as a Therapeutic
Objective in Prostate Cancer. Acta Urologica Italicay Vol
12 (1Suppl):181-182, 1998.
- Pound C, Partin A, Eisenberger M, Chan D, Pearson
J, Walsh P. The Natural History Of Progression To Metastases And
Death From Prostate Cancer In Men With PSA Recurrence Following
Radical Prostatectomy. JAMA. 281:1591-1597, 1999.
- Eisenberger C, Walsh P, Eisenberger M, Chow Nan-Haw,
Partin A, Mostwin J, Marshall F, Epstein J and Schoenberg M. Incidental
Non-Hodgkin’s Lymphoma In Patients With Localized Prostate
Cancer. Urology 53:175-179, 1999.
- Laufer M, Carducci M, Blumenstein B, Eisenberger M.
Combined Androgen Blockade (CAB) For The Treatment Of Patients With
Metastatic Prostatic Cancer: Summary Of 15 Years Of Clinical Research.
AUA Update Series Lesson 29: Volume XVIII, 1999.
- Jodrell D, Reyno L, Sridhara R. Eisenberger M,
Tkaczuk K, Zuhowski E, Sinibaldi V, Novak M, and Egorin M. Suramin:
Development of a population pharmacokinetic model and its use with
intermittent short infusions to control plasma drug concentration
in patients with prostate cancer. Classical Papers and Current
Comments, Vol 4, No 1:pp 264-273, 1999.
- Laufer M, Sinibaldi VJ, Carducci MA, and Eisenberger MA.
Rapid disease progression after the administration of bicalutamide
in patients with metastatic prostate cancer. Urology, Vol
54, No. 4:745, October 1999.
- Sinibaldi V, Carducci M, Laufer M, Eisenberger M.
Preliminary Evaluation of a Short Course of Estramustine Phosphate
and Docetaxel (Taxotere) in the Treatment of Hormone-Refractory
Prostate Cancer - Seminars in Oncology, Vol 26, No 5, Suppl
17: pp 45-48, October 1999.
- Bubley G, Carducci M, Dahut W, Dawson N, Deliani D, Eisenberger M, Figg W, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan
R, Myers C, Oh W, Petrylak D, Reed E, Roth B, Santor O, Scher H,
Simons J, Sinibaldi V, Small E, Smith M, Trump D, Vollmer R, Wilding
G. Eligibility and Response Guidelines for Phase II Clinical Trials
in Androgen-Independent Prostate Cancer: Recommendations From the
PSA Working Group. J Clin Oncol, Vol 17, No 11:3461-3467,
1999.
- Eisenberger MA and Walsh PC. Early androgen deprivation
for prostate cancer? N Eng J Med, 341:1837, 1999.
- PCTCG. Maximum Androgen Blockage In Advanced Prostate Cancer:
An Overview of the Randomized Trials - Prostate Cancer Trialists’
A Collaborative Group* - Lancet: 355:1491-98, 2000.
- Laufer M, Pound C, Carducci M and Eisenberger M.
Management Of Patients With Rising Prostate-Specific Antigen After
Radical Prostatectomy. Urology 55:309-315, 2000.
- Sinibaldi V, Eisenberger M. Preliminary Evaluation
of Docetaxel Plus 1-Day Estramustine In The Treatment Of Prostate
Cancer. Advances In Prostate Cancer, Vol 4, No 1: pp 8-10,
March 2000.
- Eisenberger MA. Editorial Comment. Urology,
Vol. 55, No. 3:395-396, March 2000.
- Small E, Meyer M, Marshall E, Reyno L, Meyers F, Natalie R, Lenehan
P, Chen L, Slichenmyer W, and Eisenberger M. Suramin
Therapy for Patients With Symptomatic Hormone-Refractory Prostate
Cancer: Results of a Randomized Phase III Trial Comparing Suramin
Plus Hydrocortisone To Placebo Plus Hydrocortisone. J Clin Oncol
Vol 18:1440-1450, 2000.
- Hussain M, Fisher E, Petrylak D, Wood D, Small E, Eisenberger M, and Crawford E. Androgen Deprivation and 4-Courses Fixed
Schedule Suramin In Patients With Newly Diagnosed Metastatic Prostate
Cancer: A Southwest Oncology Group Study. J Clin Oncol Vol
18:1043-1049, 2000.
- Sinibaldi V and Eisenberger M. Systemic Treatment of Hormone-Refractory
Prostate Cancer, Revista da Sociedade Brasileira de Oncologia. SBOC
Revista, Vol 2: 73-87, 2000.
- Laufer M, Denmeade S, Sinibaldi V, Carudcci M, Eisenberger M. Complete Androgen Blockade For Prostate Cancer: What Went
Wrong?! J Urol Vol 164:3-9, 2000.
- Laufer M, Sinibaldi V and Eisenberger M. Treatment of
Advanced Prostate Cancer. Clinical Oncology: Update Edited by: Martin
D. Abeloff, James C. Armitage, Allen S. Lichter and John E. Neiderhuber.
Vol 3, No 1:1-12, June 2000.
- Wang ZP, Eisenberger MA, Carducci MA, Partin AW, Scher
HI, and Ts’o PO. Identification and characterization of circulating
prostate carcinoma cells. Cancer 15; 88(12): 2787-2795,
June 2000.
- Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland
C, Donnelly J, Eisenberger MA, Escalante C, Hinds P, Jacobsen
PB, Kaldor P, Knight SJ, Peterman A, Piper BF, Rugo H, Sabbatini
P, and Stahl C. NCCN Practice Guidelines for Cancer-Related Fatigue.
Oncology (Hunting). 14(11A):151-161, November 2000.
- Laufer M, Schoenberg M and Eisenberger M. Paclitaxel-Induced
Stomal Neuropathy: A Unique Cause Of Pain In Patient With Ileal
Conduit. Urology 56(6):1056, Dec 20, 2000.
- Pienta K, Fisher E, Eisenberger M, Mills G, Goodwin J,
Jones J, Dakhil S, Crawford E and Hussain M. A Phase II Trial of
Estramustine and Etoposide In Hormone Refractory Prostate Cancer:
A Southwest Oncology Group Trial (SWOG-9407) - The Prostate
Vol 46, No 4:257-261, 2001.
- Thompson I, Tangen C, Tolcher A, Crawford D and Eisenberger M. African American Ethnic Background Is Associated With Significant
Reduction In Survival In Men With Metastatic Prostate Cancer: Results
Of A Randomized, Prospective Trial (SWOG-8894) JNCI Vol
93, No, 3, 2001.
- Roberts W, Carducci M, Han M, Epstein J, Eisenberger M,
Walsh P and Partin A. Contemporary Identification of Patients at
High-Risk for Early Prostate Cancer Recurrence Following Radical
Retropubic Prostatectomy. Urology 57:1033-1037, 2001.
- Small E, McMillian A, Meyer M, Chen L, Slichenmyer W, Lenehan
P and Eisenberger M. Serum Prostate-Specific Antigen Decline
as a Marker of Clinical Outcome in Hormone-Refractory Prostate Cancer
Patients: Associated With Progression-Free Survival, Pain End Points,
and Survival. J Clin Oncol Vol 19:1304-1311, 2001.
- Schroder L, Lew D, Flanigan R, Eisenberger M, Seay T,
Hammond N, Needles B and Crawford D. Phase II Evaluation Of Suramin
In Advanced Renal Cell Carcinoma – A Southwest Oncology Group
Study. Urologic Oncol Vol 6, 2001:145-148.
- Kucuk O, Fisher E, Moinpour C, Coleman D, Hussain M, Sartor O,
Chatta G, Lowe B,. Eisenberger M. and Crawford, D. Phase
II Trial of Bicalutamide (casodex) in Patients with Advanced Prostate
Cancer Who Failed Conventional Hormonal Therapy: A Southwest Oncology
Group Study (SWOG 9235) - Urology 58:2001: 53-58.
- Walsh PC, DeWeese TL, Eisenberger MA. A Structured
Debate. Immediate Versus Deferred Androgen Suppression In Prostate
Cancer: Evidence For Deferred Treatment. J. Urol Vol 166,
2001:508-516
- Carducci M, Gilbert J, Bowling K, Noe D, Eisenberger M,
Sinibaldi V, Zabelina Y, Chen T, Grochow L and Donehower R. A Phase
I Clinical and Pharmacological Evaluation of Sodium Phenylbutyrate
on a 120-h Infusion Schedule1. Clin Cancer Res 2001; 7:3047-3055.
- Eisenberger MA. Recent Developments in Chemotherapy
for Bladder Cancer Oncology. Vol 15, No. 6:779-780, June 2001.
- Walsh PC, DeWeese TL and Eisenberger MA. A Stuctured
Debate: Immediate Versus Deferred Androgen Suppression In Prostate
Cancer – Evidence for Deferred Treatment. Journal of Urology
Vol. 166, 508-516, August 2001.
- Eisenberger MA. Surgical Adjuvant Chemotherapy in High
Risk Patients With Prostate Cancer: Are We Ready For A Prime Time?
Advances in Prostate Cancer, March 2002; Vol. 6, No. 2:3-4.
- Sinibaldi V, Carducci MA, Moore-Cooper S, Laufer M, Zahurak M,
and Eisenberger MA. Phase II Evaluation of Docetaxel
plus One-Day Oral Estramustine Phosphate in the Treatment of Patients
with Androgen Independent Prostate Carcinoma. Cancer March 1, 2002;
Vol 94, No. 5: 1457-1465.
- Lassiter LK and Eisenberger MA. The Dilemma
of Patients with a Rising PSA Level After Definitive Local Therapy
for Prostate Cancer. Seminars in Urologic Oncology, May
2002; Vol. 20, No. 2:146-154.
- Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinabaldi V, Donehower R, Leahy TL, Carr RA, Isaacson
JD, Janus TJ, Andre A, Hosmane BS, and Padley RJ. Atrasentan, an
endothelin-receptor antagonist for refractory adenocarcinomas: safety
and pharmacokinetics. J. Clin. Oncol. April 15 2002, 20
(8):2171-2180.
- Eisenberger MA. Therapeutic considerations for
patients with high-risk, nonmetastatic, prostate cancer. Semin.
Urol. Oncol. August 2002, Vol 20 (3 Suppl 1):19-23.
- Lieb J, Basaria S, Tang A, DeWeese T, Carducci M, Eisenberger M and Dobs A. Long Term Effects Of Androgen Deprivation Therapy
In Prostate Cancer Patients. Clinical Endocrinology 2002;
56:779-786.
- Sokoll LJ, Bruzek DJ, Dua R, Dunn W, Mohr P, Wallerson G, Eisenberger M, Partin AW and Chan DW. Short-term stability of the molecular
forms of prostate-specific antigen and effect on percent complexed.
Urology 2002.
- Eisenberger, M. Prostate Specific Antigen. New
England Journal of Medicine, 346 (9):715, 2002.
- Eisenberger, M. Hormonal Therapy for Advanced
Prostate Cancer. The Johns Hopkins White Paper Bulletins. Prostate
Bulletin Winter Issue, 23-32, December 23, 2002.
- Laufer M., Ramalingam S, Schoenberg, MP, Haisfield-Wolf ME, Zuhowski
EG, Truehart IN, Eisenberger MA, Nativ O, and Egorin
MJ. Intravesical Gemcitabine Therapy for Superficial Transitional
Cell Carcinoma of the Bladder: A Phase I and Pharmacokinetic Study.
J Clin Oncol Vol 21, (4):697-703, 2003.
- Eisenberger M, Phase I and Clinical Pharmacology of a
Type I and II, 5 ?-Reductase Inhibitor (LY-320236) in Prostate Cancer:
Elevation of Estradiol as the Possible Mechanism of Action. Urology
2003.
- Tangen CM, Faulkner JR, Crawford ED, Thompson IM, Hirano D, Eisenberger M, Hussain M. Ten-Year Survival with Metastatic Prostate Cancer.
Clin Prost Ca, June 2003.
- Eisenberger M, Taxol induced neurotoxicity presenting
as stomal pain in a patient with ileal conduit. Urology
2003
- Eisenberger MA. A Multi-Institutional Pilot
Study of Adjuvant Docetaxel for Patients with Prostate Cancer at
High Risk for Relapse after Radical Prostatectomy. MedReviews,
Vol. 5, (Supp. 2):S42-S47, 2003.
- Eisenberger MA, Menachem L, Vogelzang NJ, Sartor
O, Thornton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci
MA, Zahurak M, and Raghavan D. Phase I and Clinical Pharmacology
of a Type I and II, 5-Alpha-Reductas Inhibitor (LY-320236) in Prostate
Cancer: Elevation of Estradiol as Possible Mechanism of Action.
J. of Urology, Vol. 63 (1):113-119, January 2004.
- Sunkara U, Walczak JR, Summerson L, Rogers T, Eisenberger M, Denmeade S, Pili R, Huff CA, Sinibaldi V, and Carducci MA.
A Phase II Trial of Temozolomide and IFN-a in Patients with Advanced
Renal Cell Carcinoma. J. of Interferon & Cytokine Research
, 24:37-41, 2004.
- Scher HI, Eisenberger MA, D’Amico AV,
Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff, et al.
Eligibility and Outcomes Reporting Guidelines for Clinical Trials
for Patients in the State of a Rising Prostate-Specific Antigen:
Recommendations From the Prostate-Specific Antigen Working Group.
J. of Clin. Onc., Vol. 22, (3), pg 537-556, February, 2004.
- Rosenbaum E, Partin A, and Eisenberger M. Biochemical
Relapse After Primary Treatment for Prostate Cancer: Studies on
Natural History and Therapeutic Considerations. JNCCN,
Vol. 2 (3); 249-256, May 2004
- D’Amico AV, Eisenberger MA, Partin AW,
Pienta KJ. Therapeutic strategies for patients with a rising PSA:
A case-based approach. Report to the Nation on Prostate Cancer 2004
(Carroll P, Nelson W Eds), Prostate Cancer Foundation,
pp. 85-92. 2004.
- Eisenberger MA, Partin AW. Progress toward identifying
the aggressive subtype of
Prostate Cancer Subtype. N Engl J Med 2004 ; 180-181.
- Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN,
Oudard S, Théodore C, Nicholas DJ, Turesson I, Rosenthal
MA and Eisenberger MA, on behalf of the
TAX 327 Investigators. Randomized comparison of weekly or three-weekly
docetaxel plus prednisone with mitoxantrone plus prednisone for
treatment of patients with advanced hormone-refractory prostate
cancer. N Engl J Med 2004 ; 1502-1512.
- Scher HI, Esinberger MA, D’Amico AV, Halabi
S, Small EJ, Morris M, Kattan MW, Roach M, KAntoff P, Pienta KJ,
Carducci MA, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D,
William B, Wilding G, Moul JW, Partin AN, Logothrtis C, Soule HR.
Eligibility & Outcomes reporting guidelines for clinical trails
for patients in the State of a Rising Prostate-Specific Antigen:
Recommendations from the PSA working Group. Sponsored by the American
Society of Clinical Oncology. Journal of Clinical Oncology
22:537-556. 2004
- Freedland SJ, Humphreys EB, Mangold LA, Partin AW, Eisenberger MA, Walsh PC. Predicting Prostate Cancer Specific Mortality
Following Biochemical Recurrence after Radical Prostatectomy. Sponsored
by the National Institute of Health/National Cancer Institute. JAMA.
2005;294:433-439.
- Bastian P, Palapattu G, Lin X, Yegnasubramanian S, Mangold L,
Trock B, Eisenber M, Partin A, Nelson W. Preoperative
Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early
Prostate-Pecific Antigen Recurrence Following Radical Prostatectomy.
American Association for Cancer Research, Vol. 11(11); 4037-4043,
2005.
- Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer
M, DeWeese TL, Eisenberger, MA. Marimastat in the
treatment of patients with biochenically relapsed prostate cancer:
A prospective randomized, double blind, phase I/II trial. Clinical
Cancer Research, Vol. 11(12); 4437-4443, 2005
BOOK CHAPTERS
- Eisenberger M, Hoth D, and Posada J. New drug
development in head and neck cancer. In: Head and Neck Oncology.
Wolf G, (ed), Boston, Massachusetts: Martinus Nuhoff Publishers,
1984.
- Eisenberger M, Posada J, Soper, and Wittes,
RE. The current status of chemotherapy. In: Head and Neck Cancer.
Wittes, R.E. (ed.), John Wiley and Sons, Ltd. Publishers, 1985.
- Marsoni S, Hurson S, and Eisenberger M. Chemotherapy
for bone metastasis. In: Bone Resorption, Metastasis and Diphosphonates.
S. Garatini (ed.), Raven Press, New York, New York, pp. 181-194,
1985.
- Eisenberger MA, Jacobs M, Drake K, Bajaj K,
Kennedy P, Elias G, and Gray W. Simultaneous treatment with carboplatin
(CBDCA) and conventional radiotherapy for unresectable loco-regional
squamous cell carcinoma of the head and neck: Phase I-II Study.
In: Head and Neck Oncology Research(editors Wolf GT and
Carey TE), p 431-435, 1988.
- Eisenberger M. Endocrine resistant prostatic
cancer: An Assessment of non-hormonal chemotherapy. In: Actualizaciones
Urological. Mello N, Zwegen E, Pontes E (eds.), Barcelona,
Spain, pp. 119-143, 1989.
- Parnes H, and Eisenberger M. Hormone releasing
factors: Oncological uses. In: Proteins and Peptides as Drugs.
Nadler, P.I., (ed). Marcell Dekker, Inc., 1989.
- Eisenberger M. Chemotherapy for head and neck
cancer. In: Cancer of the Head and Neck. Second Edition.
Suen, Myers (eds.), Churchill Livingstone Publishers, pp. 979-1004,
1989.
- Resnick M, Bagshaw M, Dorr F, Garnick M, Horton J, Prout G, Stamey
T, Scardino P, Eisenberger M, Gibbons R, Kaplan
W, Karr J, Tori F, and Trump D. Response/ progression criteria for
evaluating prostate cancer. In: Diagnostic Ultrasound of the
Prostate. Resnick, Watanabe, Karr (eds). Elsevier (publ.) pp.
88-97, 1989.
- Eisenberger M.: Chemotherapy in prostate cancer.
In: "Current Genito-Urinary Cancer Surgery."
Crawford ED, Das S (eds). Lea & Febiger, pp. 507-518, 1990.
- Eisenberger M, Chemotherapy for endocrine resistant
cancer of the prostate. In: Treatment of Prostatic Cancer: Facts
and Controversies. F. Schroder (ed). Wiley-Liss (Publisher), EORTC
Monograph 8:155-164, 1990.
- Eisenberger M, Crawford E, McLeod E, Benson
R, Spaulding J, Dorr A, Blumenstein B, Doppelblinde, Prospective
Vergleischstudies Von Leuprorelin versus Leuprorelin plus Flutamide,
In: der behandlung des Fortgeschrittenen Prostatakarzinoms. Frohmuller
HBW, Wirth MP 9eds). Springer-Verlag (publisher), pp. 41-51,
1990.
- Belani C, Egorin M, Abrams J, Hiponia D, Eisenberger M, Aisner J, Van Echo D. A novel pharmacodynamically based
approach to dose optimization of carboplatin when used in combination
with etoposide. In:Carboplatin (JM-8): Current Perspectives and
Future Directions. (Bunn PA, Canetta R, Ozols R, Rosencweig M, (eds).)
W.B. Saunders Co. Philadelphia, pp. 39-48, 1990.
- Eisenberger M. Male genital cancers: prostate
and testicle. In: Cancer: A Technical Monograph M. Mitchell
(ed). National Labs (publisher), pp 29 - 35, 1991.
- Eisenberger M. Chemotherapy for advanced prostate
cancer. In: Monographs of the European School of Oncology on
The Medical Management of Prostate Cancer L. Denis (ed) Springer-Verlag
publishers, NY, pp. 75-87, 1991.
- Belani C, and Eisenberger M. Carcinoma epdermoide
de cabeza e cuello locamente avanzado e irresecable: Tratamintos
combinados con quimiotherapia y radioterpia conventional sincronicas.
Avances en Cancer de Cabeza Y Cuello. Baron, SMAR Madrid,
Spain, Capitulo 13, pp 183-188, 1992.
- Eisenbeger MA. Chemotherapy for Carcinomas of
the Penis and Urethra. In: The Uriologic Clinics of North America.
(eds) Crawford ED, Das S. W.B. Saunders Company, Vol 19, (2):
pp 333-338, 1992
- Belani C, Eisenberger M. Quimiotherapia en el
carcinoma epidermoids de cabeza y cuello. In: Advances En Cancer
De Cabeza Y Cuello. (ed). Gonzales Baron, SMAR, Madrid, Spain, pp
205-214, 1992.
- Aisner J, Eisenberger M, and Fontanta J. Hormonal
Agents. Section Two: Chemotherapy Drugs. In: The Chemotherapy
Source Book. M.J. Perry (ed). Williams & Wilkins pp. 413-429,
1992.
- Eisenberger M, and Parnes H. Use of GNRH analogues
in oncology: prostate and breast cancer, In: Gonodotropin Hormone
Releasing Hormone Analogues, In: Infertility and Reproductive
Medicine Clinics of North America. (Ed. M.L. Polan, M.R. Henzl),
Vol. 4, (1):171-188, 1993
- Eisenberger M. Chemotherapy and Palliation in
Prostate Cancer. In: Cancer of the Prostate. Crawford ED, Das
S (eds). Marcell Dekker Inc., Chapter 17.pp 369-398, 1993.
- Eisenberger M. Genito-urinary malignancies,
In: Oncology - Current Practice of Medicine (Volume Editor
Ettinger D.), Volume 3, Section (12): 7.1-7.10, 1996.
- Aisner J, Fram R, Eisenberger M, and Fontana
J. Hormonal agents for the treatment of cancer, In: The Chemotherapy
Source Book. 2nd edition, (Williams & Wilkins, Balto.,
MD, Michael C. Perry, Editor) pg. 459-476, 1996.
- Eisenberger M. Chemotherapy for cancer of the
prostate, In: Current Genito Urinary Cancer Surgery, ED
Crawford), second edition, section XII (52), pg 667-677, 1996.
- Carducci M, Eisenberger M, Kobayashi K, Reyno
L, and Egorin M. Suramin in advanced prostate cancer. In: Comprehensive
Text Book of Genito-Urinary Oncology. Chapter 18c, Section
2. 1996
- Eisenberger M. Chemotherapy for hormone-resistant
prostate cancer, In: Campbell’s Urology , (Walsh,
Retik, Vaughn, Wein(Eds), Saunders(publ.), 7th Edition, vol. 3,
Chapter 90, pg. 2645-2658, 1997.
- Mahler C, Akaza H, Boccardo F, Coulange C, DiSilverio F, Eisenberger M, Jakse G, Tunn U, Varkarakis M, Verhelst J. Chapter 10.
Secondary hormonal treatment. In: Proceedings of the First International
Consultation on Prostate Cancer. (Murphy G, Denis L, Chatelain
C, Griffiths K, Khoury S, Cockett, Scientific Communications International)
pg. 305-324, 1997.
- Eisenberger MA. Chemotherapy for Hormone-Resistant
Prostate Cancer. In: Campbell’s Urology, Study Guide (Walsh
PC, Retik AB, Vaughan ED, Wein AJ, Editors. Saunders Publisher)
Vol 3, Section XI, Chapter 90, pg. 2645-2658 1998.
- Eisenberger MA. Chemotherapy for Hormone-Resistant
Prostate Cancer. In: Campbell’s Urology, 7th Edition
(Walsh PC, Retik AB, Vaughan ED, Wein AJ, Editors) Chapter 91, p
373, 1998.
- Eisenberger MA. New Approaches To Drug Development
in Prostate Cancer. In: Renal, Bladder and Prostate Cancer An
Update. Ed. Karl Kurth, Gerald Mickisch and Fritz Schroder,
Parthenon Publishing (PACIO V - 1998), Section 3, Chapter 24: 211-218,
1999.
- Rubben H, Schmidt J.D., Eisenberger M, Lluch
I, Pienta K.J. and Logothetis C. Treatment of Hormone Resistant
Disease. In: Prostate Cancer. Ed. G. Murphy, S. Khoury,
A. Partin and L. Denis, Chapter 11, pg 409-435, 2000.
- Schoenberg, MP, Bluemke DA, Carducci MA, DeMarzo AM, DeWeese
TL, Eisenberger MA, Mandavili S, Rosenthal DL,
Sinibaldi VJW, Walker JM, Willmann J, and Wills Marcia. The
Guide to Living with Bladder Cancer, 2000.
- Eisenberger MA. Non-Endocrine Systemic Approaches
For Prostate Cancer: Current Status And Future Directions. In: Renal,
Bladder and Prostate Cancer An Update. Ed. Fritz Schroder,
Parthenon Publishing. Chapter 24, pg 219-228, 2001.
- Eisenberger M and Carducci M. Chemotherapy for
hormone-resistant prostate cancer, In: Campbell’s Urology,
(Walsh, Retik, Vaughn, Wein (Eds), Saunders (publ.), 2th Edition,
Chapter 95, pg 336-339, 2002.
- Eisenberger MA, and Carducci MA. Chemotherapy
for Hormone-Resistant Prostate Cancer, Ed. G. Murphy, S. Khoury,
A. Partin and L. Denis, Vol. 4, Chapter 95, pg 3209, 2002.
- Nelson WG, Carter HB, DeWeese TL, Bajaj G, Thompson TL, and Eisenberger MA. Prostate Cancer. In: Clinical Oncology, (Abeloff
MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG. 3rd Edition,
Chapter 87, pg 2085-2148, 2004.
- Eisenberger MA. Controversies in hormone treatment
for prostate cancer, In: Prostate Cancer, Principles & Practice.
Nartub Dybutz Ktd (Taylor & Francis Group). Section F, Chapter
32, 2005.
BOOK CHAPTERS- (IN PRESS)
- Laufer M. and Eisenberger MA. Prognostic Factors
for Response and Survival with Hormone Therapy - (In Press- 2003).
- Laufer M. and Eisenberger MA. TxNxM1 - The Case
For Monotherapy - (In Press - 2003)
- Eisenberger MA, The current knowledge of hormonal
therapy in the treatment and prevention of prostate cancer –
(In Press- 2005)
ABSTRACTS
- Kaplan R, Eisenberger M, Silverman M, and Lessner H. Four-drug
combination chemotherapy of advanced GI malignancy. Digestion
16:249, (Israel - 1977).
- Eisenberger M, Denefrio J, Mansell P, and Silverman
M. Combination chemotherapy with bleomycin and hydroxyurea in advanced
head and neck cancer. Presented at the U.I.C.C. Meeting, Buenos
Aires, Argentina, Proceedings U.I.C.C., 1978.
- Eisenberger M, Denefrio J, Kaplan D, Silverman M,
and Lessner H. Combination chemotherapy with bleomycin and hydroxyurea
in advanced head and neck cancer. Proc Am Soc Clin Oncol/Am
Assoc Cancer Research, 21:343(C-97), San Diego, 1980.
- Eisenberger M, Pereiras R, Solomon J, and Lessner
H. Combination chemotherapy with cis-dichlorodiammine-platinum (DDP)
and cytosine arabinoside (CA) given by intra-arterial (IA) or intravenous
(IV) infusion in patients (Pts) with metastatic colorectal cancer.
Proc Am Assoc Cancer Research/Am Soc Clin Oncol 22:453,
1981.
- Kumar K, Eisenberger M, Broder L, and Love N. Non-pulmonary
small cell carcinoma (SCC): Response to combination chemotherapy
(CT). Proc Am Assoc Cancer Research/Am Soc Clin Oncol 22:528,
1981.
- Warner B, Santen R, Demers L, Max D, Lohman P, Smith J, Muss
H, Resnick M, Glode M, Wettlaufer J, Eisenberger M,
and Block N. Effects of (D-LEU6DES-GLY-NH210, pro-ethylamide9) GnRH
(LEUPROLIDE) pm steroidogenesis when used to treat prostatic carcinoma.
Proc Am Assoc Andrology, 1981.
- Eisenberger M. Chemotherapy of salivary gland tumors
- A preliminary report. Proc Florida Society Clinical Oncology,
1982.
- Eisenberger M, Ariel M, Broder L, Allen L, and Diamonti
G. Comprehensive Cancer Center for the State of Florida, University
of Miami School of Medicine, Florida A & M University, and V.A.
Medical Center, Miami, Florida. Phase I-II of guanazole (GZ) by
intermittent intravenous (IV) infusion in patients with advanced
carcinoma (CA). Proc 13th International Cancer Congress,
1982.
- Vogel CL, Gorowski E, and Eisenberger MA. Phase
I trial of weekly ICRF-187. Proc Am Soc Clin Oncol, 1982.
- Warner B, Santen R, and members of the Abbott Study Group. Successful
"Medical Castration" with a superagonist analog of gonadotropin
releasing hormone (GnRH) in treating prostatic carcinoma. Proc
Am Soc for Clin Invest, 1982 (Presented by Warner, B.)
- Glode L (for the Abbott Prostatic Cancer Study Group). Leuprolide
therapy of advanced prostatic cancer, Proc Am Soc Clin Oncol,
1982.
- Singer J, Eisenberger M, Block N, and Politano
V. A comparison of prostate cancer treated with GnRH or DES. Poster
presentation. Proc Am Urological Assoc, New Orleans, 1984.
- Singer J, Block N, Eisenberger M, and Politano
V. A comparative analysis of a gonadotropin releasing hormone and
diethylstilbestrol. Presented at the South Section of Am Urological
Assoc, Atlanta, 1984.
- Eisenberger M, Ellenberg S, Jones B, and Friedman
M. The advantages of early stopping rules in randomized trials for
head and neck cancer. Proc Am Soc Clin Oncol C-520: 134,
1985.
- Kalash S, Eisenberger M, Henzl M, and Hoffman.
Effective sustained androgenic suppression with (D-Nal(2)6-LHRH)
agonist. Proc Am Urological Assoc, National Meeting, New York,
N.Y., 396:203(a), 1986.
- Eisenberger M, Silva H, Kalash S, Henzl M, Hoffman
P, and Members of the Nafarelin Study Group. Effective long-term
androgenic suppression and clinical benefits with nafarelin acetate:
a new intranasal LHRH analog for prostatic cancer. Proc Am Soc
Clin Oncol, C-417, 1986.
- Silva H, Abrams J, Olver I, Eisenberger M, Tchekmedyian
N, Leavitt R, Abrams J, and Aisner J. Phase II trial of n-methylformamide
in patients with unresectable or recurrent renal cell carcinoma.
Proc Am Soc Clin Oncol 357:92, 1986, Los Angeles.
- Tchikmedyian N, Kaplan R, Elias E, Eisenberger M,
Abrams J, and Van Echo D. Phase II study of n-methyloformamide in
colorectal cancer. Proc Am Soc Clin Oncol 416:107, 1986,
Los Angeles.
- Conley B, Silva H, Hornedo J, Eisenberger M, and
Aisner J. Phase II Trial of 4'deoxdoxorubicin in patients with non-small
cell lung cancer. Proc Am Soc Clin Oncol 727:185, 1986,
Los Angeles.
- Crawford D, McLeod D, Spaulding J, Benson R, Eisenberger
M, and Blumenstein B. A comparison of leuprolide with flutamide
and leuprolide in previously untreated patients with clinical stage
D2 cancer of the prostate, phase III – Intergroup - 0036.
Proc AUA 610:256(A), 1987.
- Eisenberger M, Bajaj K, Kennedy P, Jacobs M, Elias
G, and Gray W. Phase I-II study of simultaneous rt and weekly carboplatin
for unresectable head and neck cancer. Proc Am Soc Clin Oncol
531:135, 1987.
- Kennedy P, Eisenberger M, et al. Toxicity with
carboplatin in combination with methotrexate in patients with recurrent
head and neck cancer. Proc Am Soc Clin Oncol 533:136, 1987.
- Eisenberger M, Jacobs M, Bajaj K, Kennedy P, Drake
K, Elias G, and Gray W. Simultaneous treatment with carboplatin
(CBDCA) and conventional radiotherapy for the treatment of patients
with advanced unresectable squamous cell carcinoma of the head and
neck. Preliminary results of a phase I-II trial. Proc Second
International Head and Neck Oncology Research Conference, Abst.
No. 1.9, Arlington Virginia, September 1987.
- Crawford D, McLeod D, Dorr A, Spaulding J, Benson R, Eisenberger
M, and Blumenstein B. A comparison of leuprolide with flutamide
and leuprolide in clinical stage D2 cancer of the prostate. South
Central Section of the Am Urological Association (1987).
- Kelsen D, Nanus D, Lipperman R, and Eisenberger M.
Phase II trial of ifosfamide in epidermoid of the esophagus. Proc
Am Soc Clin Oncol 340:1987, Atlanta.
- Belani C, Van Echo D, Eisenberger M, Conley B,
Hiponia D, Markus S, and Aisner J. A Phase II study of caracemide
in advanced or recurrent non-small cell lung cancer. Proc Am
Soc Clin Oncol 708:180, 1987, Atlanta
- Melink T, Van Echo D, Tait M, Abrams J, Eisenberger M,
and Aisner J. Phase II trial of caracemide (NSC253272) administered
by 5-day continuous infusion in advanced colorectal carcinomas.
Proc Am Soc Clin Oncol 438:114, 1988.
- Tait N, Abrams J, Egorin M, Cohen A, Eisenberger M,
and Van Echo D. Phase II carboplatin (CBCDA) for metastatic renal
cell cancer with a standard dose and a calculated dose according
to renal function. Proc Am Soc Clin Oncol 484:125, 1988.
- Belani C, Abrams J, Egorin M, Eisenberger M, Hiponia
D, Van Echo DA, Schimpff SC, and Aisner J. Phase II study of carboplatin
and etoposide for non-small cell lung cancer using pharmacologically
based dosing. Proc Am Soc Clin Oncol 829:214, 1988.
- Eisenberger M, Krasnow S, and Ellenberg V. A comparison
of carboplatin and methotrexate vs. MTX in recurrent head and neck
cancer. Proc Am Soc Clin Oncol 504:153, 1988.
- Sinibaldi V, Eisenberger M, Jacobs M, Engstrom
C, Elias G, Drake K, Gray W, Van Echo D, and Abrams J. Simultaneous
carboplatin and conventional radiotherapy in advanced unresectable
squamous cell carcinoma of the head and neck. Proc Am Soc Clin
Oncol, 503:153, 1988.
- Crawford E, McLeod D, Dorr A, Spaulding J, Benson R, Eisenberger
M, and Blumenstein B. Treatment of newly diagnosed stage D2
prostate cancer with leuprolide and flutamide or leuprolide alone.
Phase III - intergroup, study 0036, Proc Am Soc Clin Oncol,
460:119, 1988. (Presented at the plenary session - 5-selected abstracts/year).
- Crawford E, McLeod D, Dorr A, Spaulding J, Benson R, Eisenberger
M, and Blumenstein B. Treatment of newly diagnosed state D2
prostate cancer with leuprolide and flutamide or leuprolide alone.
Phase III-Intergroup, study 0036, Proc Am Urology Assoc,
4,706:139, 1988, Boston, MA.
- Jacobs M, Eisenberger M, Sinibaldi V, Gray W, and Salazar O.
Carboplatin and radiotherapy for stage IV carcinoma of the head and
neck. Radiation Oncology, Physics, 15:138(44), 1988. Presented by
Dr. Jacobs at the Am Soc Therap Rad Oncol Meeting in New Orleans,
Louisiana.
- Van Echo D, Hiponia D, Abrams J, Eisenberger M, Kaplan
R, and Aisner J. A phase II study of IPROPLATIN (CHIP) in advanced
malignant melanoma. Proc Am Soc Clin Oncol 984:754, 1988.
- Eisenberger M, Crawford E, Benson R, McLeod D, Dorr A,
and Spaulding J. Significance of pretreatment stratification by
extent of disease in stage D2 prostate cancer patients treated with
leuprolide + flutamide or leuprolide + placebo. Presented at
the Am Soc Clin Oncol, 1989,San Francisco.
- Sinibaldi V, Eisenberger M, Jacobs M, Elias G, Abrams
J, Gray W, Van Echo D, and Aisner J. Simultaneous carboplatin and
radiation therapy for unresectable stage IV head and neck cancer.
Presented by V. Sinibaldi, Am Soc Clin Oncol, 1989 San
Francisco.
- McLeod D, Blumenstein B, Eisenberger M, Crawford E, Spicer
D, Spaulding D, Dorr A, and Benson R. Evaluation of complete androgen
blockade with flutamide added to euprolide after progression to
leuprolie alone. Proc Am Soc Clin Oncol, A-526 p.136, 1990,
Washington D.C.
- Eisenberger M, Blumenstein B, and Crawford E. Evaluation
of chemotherapy in prostate cancer patients with measurable versus
bone disease only. Proc Am Soc Clin Oncol, A-596, p.153,
1990, Washington, D.C.
- Kruter F, Sinibaldi V, Engstrom C, Abrams J, Jacobs M, and Eisenberger
M. Phase II trial with IV 6-thioguanine in recurrent head and
neck. Proc Am Soc Clin Oncol A-700, p. 181, 1990, Washington,
D.C.
- Belani C, Hiponia D, Engstrom D, Fishbein G, Eisenberger M,
and Aisner J. Combination of mitoxantrone and cisplatin for patients
with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol
A-924, 1991, Houston, Texas.
- Jacobs M, Eisenberger M, Sinibaldi V, Belani C, and Gray
W. Simultaneous treatment with carboplatin, bleomycin and radiation
therapy for unresectable head and neck carcinomas. Proc Am Soc
Clin Oncol A-691, p. 207, 1991, Houston, Texas.
- Jodrell D, Zuhowski E, Egorin M, Sinibaldi V, Forrest S, and
Eisenberger M. Intermittent bolus dosing with suramin: the
use of adaptive control with feedback (ACF). Proc Am Soc Clin
Oncol A-237, p.92, 1991, Houston, Texas.
- Crawford E, Moon T, Stone M, Blum D, Becker M, Bergen R. Eisenberger
M, et al. Prostate Cancer Awareness Week. Proc Am Soc Clin
Oncol A-531, p.167, 1991, Houston, Texas.
- Eisenberger M, Jodrell D, Sinibaldi V, Zuhowski E, Jacobs
S, and Egorin M. Preliminary evidence of anti-tumor activity against
prostate cancer in a phase I trial with suramin. Proc Am Soc
Clin Oncol A-537, p.168, 1991, Houston, Texas.
- Eisenberger M, Melink T, Thompson R, Reyno L, Sinibaldi
V, et al. Changes in serum PSA levels in patients (PTS) with hormone
refractory prostate cancer (HRPCa) treated with suramin. Am
Urol Assoc, Inc. (October 1, 1991).
- Eisenberger M, Sinibaldi V, Jodrell D, Reyno L, et al.
Activity of suramin in hormone refractory prostate cancer (PC):
University of Maryland experience. Am Urol Assoc, Inc.
(October 1, 1991).
- Eisenberger M, Crawford E, Blumenstein B, Dorr A, McLeod
D, and Wolf M. Leuprolide with or without flutamide for stage D2
prostate cancer: Prognostic significance of minimal disease. Am
Soc Clin Oncol 1992 San Diego, California.
- Crawford E, Eisenberger M, McLeod D, and Blumenstein B. Treatment
of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide
or leuprolide alone. American Urological Association, 1992 Washington
DC.
- Eisenberger M, Sinibaldi V, Tkaczuk K, Reyno L, Jacobs
S, and Egorin M. Activity of suramin in hormone refractory prostate
cancer: Phase I. Am Urol Assoc, 1992 Washington, D.C.
- Tkaczuk K, Eisenberger M, Reyno L, Sinibaldi V, and Egorin
M. Preliminary activity of suramin in hormone refractory prostate
cancer. Am Soc Clin Oncol, 1992 San Diego, California.
- Eisenberger M, Reyno L, Sinibaldi V, et al. Predictive
value of PSA changes in prostate cancer on Suramin. Am Soc Clin
Oncol, 1993, Orlando, Florida.
- Staggers F, DeAntoni E, Crawford E, Stone N, Blum D, Berger R,
Eisenberger M, and Gambert S. A profile of African-american
participants in prostate cancer awareness week, 1992. Proc.
Am Urol Assoc, (Abstr. 255, 2q1 A,) 1994, San Francisco, CA.
- Reyno L, Eisenberger M, Sridhara R, Sinibaldi V, and Egorin
M. Safety and efficacy of a pharmacologically derived fixed treatment
schedule of suramin in stage D3 prostate cancer. Proc Am Soc
Clin Onc, (Abstr 729 p.236,) 1994, Dallas ,Texas.
- Aisner J, Jacobs M, Gray W, Sridhara R, Sinibaldi V, Belani C,
and Eisenberger M. Weekly carboplatin and weekly, carboplatin
with twice-weekly bleomycin each with concurrent RT for locally
advanced head and neck cancer. Proc Am Soc Clin Onc (Abstr
#0, 02, p.280,) 1994.
- Eisenberger M, Sinibaldi V, Reyno L, and Sridhara R. Development
of an active and tolerable out patient schedule of Suramin for patients
with hormone refractory prostate cancer Proc. Am Urol Assoc
Abst. #43, 238A, 1994, San Francisco, CA
- Crawford E, Eisenberger M, Blumenstein B, McLeod D, Culkin
D, Bueschen A, Thompson J, and Lowe B. Treatment of histologically
confirmed D2 prostate cancer. A comparison of bilateral orchiectomy
with or without flutamide (intergroup study 0150). Proc Am Urol
Assoc (Abst. #44, 238-A,) 1994, San Francisco, CA
- Stone N, Blum D, DeAntoni E, Crawford E, Schmid K, Eisenberger
M, Berger R, Staggers F, and Gambert S. Prostate cancer risk
factor analysis among > 50,000 men in a national study of PSA.
Proc. Am Urol Assoc (Abst. #201, 278-A,) 1994, San Francisco,
CA.
- Elder K, Eisenberger M, Sridhara R, Reyno L, Sinibaldi
V, and Egorin M. Evaluation of a flutamide withdrawal factor on
responses to suramin in stage D3 prostate cancer. Proc. American
Society of Clinical Oncology, Abst.# 778, p.248, 1994.
- Hemady R, Sinibaldi V, and Eisenberger M. Ocular symptoms
and signs associated with suramin treatment for metastatic cancer
of the prostate (P022) Opthalmology 101(suppl): 91, 1994.
- Eisenberger M, Crawford E, McLeod D, Hussain M, Loehrer
P, and Blumenstein B. The prognostic significance of prostate specific
antigen (PSA) in stage D2 prostate cancer (PC) interim evaluation
of intergroup study 0105. Proc. American Society of clinical
Oncology, Abst.# 613, p. 235, 1995.
- DeAntoni E, Crawford E, Stone N, Blum D, Staggers F, Berger E,
Eisenberger M, and Gambert S. A profile of Latino participants
in prostate cancer awareness week. Am Urol Assoc, 1995,
Las Vegas, NV.
- DeAntoni E, Ross C, Crawford E.D, Hirano D, Blum D, Berger E.R,
Stone N, Eisenberger M, Gambert S, McLeod D. Time since vasectomy
cannot be separated from age as risk for prostate cancer. South-Central
Section, AUA, 1995.
- Chaudhry V and Eisenberger M. Suramin-induced peripheral neuropathy-clinical
and electrophysiological features. The American Neurological Association,
1995.
- Sridhara R, Eisenberger M, Sinibaldi V, Reyno L and Egorin
M. Evaluation of PSA as a surrogate endpoint for response of hormone
refractory prostate cancer to suramin. Proc Am Soc Clin Oncol,
14:85(Abstr 40), 1995.
- Eisenberger M, Crawford ED, Blumenstein B, Hussain M and
McLeod D. The prognostic significance of PSA in stage d2 patients.
Proc Am Soc Clin Onc 14:235 (Abstr 613), 1995.
- DeAntoni E, Crawford E, Ross, Colleen A, Blum D, Berger E, Nelson
N, Eisenberger M, Gambert S, McLeod D, Staggers F. Age and
race-specific reference ranges for prostate-specific antigen from
a large, community-based study. Am Urol Assoc, 1996, Orlando,
FL.
- Small EJ, Marshall F, Natale R, Meyers F, Lenehan P, Boyea T,
Eisenberger M. A multicenter phase III trial of suramin +
hydrocortisone vs. placebo + hydrocortison in metastatic hormone-refractory
prostate cancer: favorable safety profile. Proc Am Soc Clin
Onc 15:254 (Abstr 655), 1996.
- Kucuk O, Blumenstein B, Moinpur C, Lew D, Coleman D, Eisenberger
M and Crawford D. Phase II trial of casodex in advanced prostate
cancer patients who failed conventional hormonal manipulation: a
SWOG study. Proc Am Soc Clin Onc, 15:245(Abstr 618), 1996.
- Baker SD, Diasio R, Lucas VS, Khor SP, Thomas S, Sartorius S,
Donehower R, Eisenberger M, Grochow L, O’Reilly S,
Hohneker J and Rowinsky E. Phase I and pharmacologic study of oral
5-fluorouracil on a chronic 28-day schedule in combination with
the DPD innactivator 776C85. Proc Am Soc Clin Oncol, 15:486(Abstr
547) 1996.
- Bowling M, Nelson J, Tong K, Simons J, Eisenberger M,
Sinibaldi V, Donehower R, and Carducci M. Biomarker responses in
men with advanced prostate cancer (PCA) to infusional phenylbutyrate
(PB). Proc Amer Soc Clin Onc, Abst.# 43, p.94, 1996.
- Carducci M, Bowling M, Eisenberger M, Sinibaldi V, Simons
J, Chen T-L, Noe D, Grochow L, and Donehower R. Phenylbutyrate (PB)
for refractory solid tumors: a phase I clinical and pharmacologic
evaluation. Proc Amer Soc Clin Onc, Abst. #1542, p.485,
1996.
- Harbaugh B, Roth B, Eisenberger M, Langleben A, Allen
R, Rasmussen H. Marimastat, a novel matrix metalloproteinase inhibitor
in patients with hormone-refractory prostate cancer. Proc Amer
Soc Clin Onc 15:258(Abstr. 671) 1996.
- Carducci M, Bowling M, Eisenberger M, Sinibaldi V, Simons
W, Chen T, Noe D, Grochow L, Donehower R. Phenylbutyrate (PB) for
refractory solid tumors: a phase I clinical and pharmacologic evaluation.
Proc Amer Soc Clin Onc 15:484(Abstr. 1542) 1996
- Bowling M, Nelson, J, Tong K, Simons J, Eisenberger M,
Sinibaldi V, Donehower R, Carducci M. Biomarker responses in men
with advanced prostate cancer to infusional phenylbutyrate. Proc
Amer Soc Clin Onc 15:94(Abstr. 43) 1996.
- Kucuk O, Blumenstein B, Moinpour C, Lew D, Coleman D, Eisenberger
M, Crawford D. Phase II trial of casodex in advanced prostate
cancer patients who failed conventional hormonal manipulation: A
SWOG Study. Proc Amer Soc Clin Onc 15:245(Abstr.618) 1996.
- DeAntoni E, Holthaus K, Crawford E.D, Stone N, Blum D, Berger
E.R, Gambert S, Eisenberger M, Staggers F, and McCloud D.
Prostate-Specific antigen (PSA) velocity in a national cohort tested
serially with three annual tests. Proc Am Urol Assoc Annual
Meeting, 157:57 (Abstr 216) April 1997.
- Cook D, Sinibaldi V, Carducci M, Schneyer C, Dobs A and Eisenberger
M. Osteopenia in men with prostate cancer treated with androgen
deprivation. Proc Am Urol Assoc Annual Meeting, 157:232
(Abstr 906) April 1997.
- Crawford E.D., Eisenberger M, McLeod D, Wilding G, and
Blumenstein B. Comparison of bilateral orchiectomy with or without
flutamide for the treatment of patients with stage D2 adenocarcinoma
of the prostate: results of NCI intergroup study. Proc Am Urol
Assoc Annual Meeting, 157:336 (Abstr 1311) April 1997.
- Mosher T, Bluemke D, Fishman E, Schoenberg M, Eisenberger
M, and DeWeese T. Multimodality treatment planning for bladder
cancer: MR and CT evaluation. Am Reontgen Ray Soc Annual Meeting,
May 1997.
- Eisenberger M, Crawford E.D, McLeod D, Loehrer P, Wilding
G, and Blumenstein B. A comparison of bilateral orchiectomy (orch)
with or without flutamide in stage D2 prostate cancer (PC) (NCI
INT-0105 SWOG/ECOG). Proc Am Soc Clin Onc Annual Meeting,
16:2a (Abstr 3 plenary session), May 1997.
- Moinpour C, Savage M, Lovato L, Troxel A, Skeel R, Eisenberger
M, Crawford E.D, Meyskens F, Jr. Quality of life endpoints in
advanced stage prostate cancer: a randomized, double blind study
comparing flutamide to placebo in orchiectomized stage D2 prostate
patients. Proc Am Soc Clin Onc Annual Meeting 16:53a (Abstr
183), May 1997.
- Long G.S, Sinibaldi V, Carducci M, O’Reilly S, Grochow
L, Noe D, and Eisenberger M. Phase I/II study of suramin
and topotecan in patients with hormone refractory prostate cancer
(HRPC). Proc Am Soc Clin Onc Annual Meeting 16:242a (Abstr
855), May 1997.
- Cook D, Sinibaldi V, Carducci M, Schneyer C, Dobs A, Eisenberger
M. Osteopenia in men with prostate cancer treated with androgen
deprivation. Proc Am Soc Clin Onc Annual Meeting 16:312a
(Abstr 1111), May 1997.
- Sinibaldi V, Carducci M, Abeloff M, and Eisenberger M.
Experience with casodex in patients with stage D3 prostate cancer.
Proc Am Soc Clin Onc Annual Meeting 16:313a (Abstr 1116),
May 1997.
- Boasberg P, Harbaugh, Eisenberger M, Harris J, Langleben
A, Ahmann F, Roth B, Berkheimer M, and Rasmussen H. Marimastat in
patients with hormone-refractory prostate cancer: a dose-finding
study. Proc Am Soc Clin Onc Annual Meeting 16:316a (Abstr
1126), May 1997.
- Sinibaldi, V.J., Long, G.S., Chaudhry, V., Carducci, M.A., Reyno,
L.M., O’Reilly, S.Chen, T.L., Sridhara,R., and Eisenberger,M.A.
Phase I and pharmacologic evaluation of a monthly, daily times five
days (D), schedule (SCH) of suramin (S) in patients with hormone
refractory prostate cancer (HRPC). Proceedings of the American
Society for Clinical Oncology, 17(A- 841):218a, 1998.
- Long, G.S., Sinibaldi, V.J., O’Reilly, S., Carducci, M.A.,
Growchow, L.B., Reyno, L., Enger, c., and Eisenberger, M.A. Phase
I and pharmacologic study of suramin (S) and Topotecan (T) in patients
with hormone refractory prostate cancer (HRPC). Proceedings
of the American Society for Clinical Oncology, 17(A- 948):
247a, 1998.
- Carducci, M., Bowling, M., Eisenberger, M., Sinibaldi, V.,Chen,
T-L., Buckley, N., Grochow, L., Noe, D., and Donehower, R. Oral
Sodium Phenylbutyrate (PB) for Refractory Solid Tumors: Phase I
and Bioavailability Assessment. Proceedings of the American
Society for Clinical Oncology, 17(A- 831):215a, 1998.
- Laufer, M., Sinibaldi, V., Wang, Z.P., Ts O, P., Partin, A.,
Carducci, M., and Eisenberger, M. Detection and phenotypic characterization
of circulating prostate cancer cells in patients with metastatic
hormone refractory prostate cancer (HRPC): A pilot evaluation. Proceedings
of the American Society for Clinical Oncology, 18(A-1329):
345a, 1999.
- Sinibaldi, V., Carducci, M., Moore-Cooper, S., Enger, C., Laufer,
M., Wolfe, A., and Eisenberger, M. A phase II study evaluating a
one-day course of estramustine phosphate (EMP) and docetaxel (D)
in patients (Pts) with hormone refractory prostate cancer (HRPC).
Proceeding of the American Society for Clinical Oncology,
18(A-1239):322a, 1999.
- Sinibaldi, V.J., Carducci, M.A., Moore-Cooper, S., Laufer, M.,
and Eisenberger, M.A. A phase II study evaluating docetaxel (D)
and one day of estramustine phosphate (EMP) in patients (PTS) with
hormone refractory prostate cancer (HRPC): Updated preliminary analysis.
Proceedings of the American Society for Clinical Oncology,
19:346a (1361), New Orleans, LA, 2000.
- Eisenberger, M., Sinibaldi, V., Laufer, M., and Carducci, M.
Phase I / + pharmacokinetic evaluation of marimastat in patients
(PTS) with advanced prostate cancer: identification of the biologically
active dose. Proceedings of the American Society for Clinical
Oncology, 19:336a (1320), 2000.
- Lieb II, J., Walters, R., Carducci, M., Eisenberger, J., DeWeese,
G., Tang, T., Dobs, A.; Johns Hopkins University School of Medicine,
Baltimore, MD; Tufts University School of Public Health, Boston,
MA. Decreased bone density and increased bone resorption in men
with prostate cancer who have been androgen deprived. Proceedings
of the American Society for Clinical Oncology, 19:333a (1310),
2000.
- Laufer, M., Thortone, D., Eisenberger, M., Vogelzang, N., Mills,
G., Raghavan, D.; Johns Hopkins University, Baltimore, MD; Eli Lilly
and Company Indianapolis, IN; University of Chicago, Chicago, IL;
University of Couth California, Los Angeles, CA. Phase I study of
escalating doses of the dual-action 5-? reductase inhibitor LY320236
in patients (Pts) with advanced prostate cancer: preliminary clinical
and hormonal results. Proceedings of the American Society for
Clinical Oncology, 19:369a (1461), 2000.
- Sinibaldi, V., Carducci, M., Moore-Cooper, S., Laufer, M., Zahurak,
M., and Eisenberger, M. A phase II study evaluating docetaxel (D)
and one day of eatramustine phosphate (EMP) in hormone refractory
prostate cancer (HRPC). Annals of Oncology: Abstract Book of
the 25th ESMO Congress, 11 [suppl 4], # 341P, October, 2000.
Hamburg, Germany.
- Sinibaldi, V., Laufer, M., Eisenberger, M., Vogelsang, N., Mills,
G., Sartor, O., Raghavan, D. A multicenter Phase I/II Clinical and
Pharmacological Evaluation of a Type I and II 5 Alpha Reductase
Inhibitor (LY320236). Proceedings of the American Society for
Clinical Oncology, 20:186a (743), San Francisco, California,
2001.
- Eisenberger, M., Laufer, M., Sokoll, L., Sinibaldi, V., Zahurak,
M., Crawford, D. Sequential evaluation of multiple potential bio-markers
in patients with metastatic prostate cancer (PCA) following androgen
deprivation. Proceeding of the American Society for Clinical
Oncology, 20:190a (758), San Francisco, California, 2001.
- Schrodr LE, Glass T, Eisenberger M, Culkin D, Buowski
R, Crawford E; University of Cincinnati, OH. Proceeding of the
American Society for Clinical Oncology, 20:153b (2361), San
Francisco, California, 2001.
- Walsh PC, DeWeese TL and Eisenberger MA. A Stuctured Debate:
Immediate Versus Deferred Androgen Suppression In Prostate Cancer
– Evidence for Deferred Treatment.The Journal of Urology Vol.
166, 508-516, August 2001.
- Egorin, M.J., Suhowski, E.G., Laufer, M., Trueheart, I., Haisfield-Wolf,
M.E., Nativ, O., Eisenberger, M., Schoenberg, M.;
University of Pittsburgh Cancer Institute, Pittsburgh, PA; The Johns
Hopkins Hospital, Baltimore, MD; Bnai-Zion Medical Center, Haifa,
Israel. Plasma pharmacokinetics and urinary recovery of intravesically
administered gemcitabine. Proceedings of the American Society
for Clinical Oncology, 21:90a (359), 2002
- Tangen, C., Crawford, E.D., Faulkner, J., Thompson, I., Eisenberger,
M., Hussain, M., SWOG Statistical Center, Seattle, WA:
University of Colorado Health Sciences Center, Denver, CO; University
of Texas Health Sciences Center at San Antonio, San Antonio, TX,
Johns Hopkins University, Baltimore, MD, Wayne State University,
Detroit, MI. Ten-year survival in patients with metastatic (M+)
prostate cancer (CaP): analysis of Southwest Oncology Group (SWOG)
8894. Proceedings of the American Society for Clinical Oncology,
21:188a (749), 2002.
- Sartor, A.O., Tangen, C., Hussain, M., Eisenberger, M.,
Crawford, E.D.; LSU Medical School, New Orleans, LA: SWOG, Seattle,
WA; Wayne State University, Detroit, MI; Johns Hopkins, Baltimore,
MD; University of Colorado, Denver, CO. Anti-androgen withdrawal
in prostate cancer: results from SWOG 9426. Proceedings of the
American Society for Clinical Oncology, 21:197a (785), 2002.
- Crawford D, Faulkner J, Thompson IM, Eisenberger MA,
Tangen CM, Hussain MH. Ten-Year Survival In Patints with Metastatic
(M=) Prostate Cancer (CAP): Analysis of Southwest Oncology Group
(SWOG) 8894. AUA Program Abstracts, Vol 167 (4):304 (Abstr.
1202), 2002.
- Sinibaldi V, Carducci M, Denmeade S, Pili R, Zhurak M, Eisenberger
M; The Johns Hopkins University, Baltimore, MD. A randomized,
double-blinded, phase I/II study of 3 doses of Marimastat in patients
with hormone naïve, biologically relapsed (M0) prostate cancer
(PCA). Proceedings of ASCO Vol 2:164b (Abstr. 2474), 2002.
- Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, and Walsh
PC. Biochemical (Prostate Specific Antigen) Recurrence Probability
Following Radical Prostatectomy For Clinically Localized Prostate
Cancer. J. of Urology, Vol. 169:517-523, February 2003.
- Eisenberger MA, Partin AW, Pound C, Roostelaar CV, Epstein
J, Walsh P; Johns Hopkins University, Baltimore, Maryland. Natural
history of progression of patients with biochemical (PSA) relapse
following radical prostatectomy. Annual Meeting, ASCO,
p.123 (Abstr 1527), 2003.
- Rosenbaum E, Sinibaldi V, Carducci MA, Zahurak M, Pili R, Denmeade
S, Sokoll L, Epstein J, Partin A, Eisenberger M; Johns Hopkins
University, Baltimore, Maryland. Evidence of a dose/response relationship
with marimastat in patients with biochemicaly relapsed prostate
cancer (PCa). Proceedings of ASCO, p. 439 (Abstr. 1762),
2003.
- Sinibaldi V, Garrett E, Rosenbaum E, DeWeese T, Carducci MA,
Pili R, Eisenberger M; The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins, Baltimore, Maryland. The outcome of androgen
suppressed prostate cancer (PCa) patients after biochemical (PSA)
relapse and no clinical/radiological evidence of metastasis (MO).
Proceedings of ASCO, p. 443 (Abstr. 1778), 2003.
- Partin AW, Humphreys EB, Mangold LA, Klicos N, Eisenberger
M, Walsh P, Baltimore, MD. Prostate Specific Antigen Doubling
Time After Radical Prostatectomy As A Predictor of Cause Specific
Survival .The Journal of Urology, AUA Annual Meeting, p.
382 (Abstr. 1451), 2004.
- Partin AW, Eisenberger M, Sinibaldi V, Humphreys
E, Mangold LA, Klicos N, Walsh P; Department of Urology and Sidney
Kimmel Comprehensive Cancer Center, The Johns Hopkins University,
Baltimore, MD. Prostate Specific Antigen Doubling Time (PSADT) Predicts
For Distant failure And Prostate Cancer Specific Survival (PCSS)
In Men With Biochemical Relapse After Radical Prostatectomy (RP),
Annual ASCO Meeting, p. 394 (Abstr. 4555), 2004.
- Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin
S, Morales A, Curley T, Delacruz A, Webb IJ, Scher HI; Memorial
Sloan Kettering Cancer Center, New York, NY; Johns Hopkins Medical
Institutions, Baltimore, MD; Millennium Pharmaceuticals, Cambridge,
MA. Phase I trail of MLN2704 in patients with castrate-metastatic
prostate cancer (CMPC). Annual ASCO Meeting p. 403 (Abstr.
4592), 2004.
- Rosenbaum E, Kibel A, Roth BJ, Wilding G, Dreicer R, Shatta B,
Petrylak D, Dipaola RS, Beer TM, Eisenberger MA; The Sidney
Kimmel Comprehensive Cancer Center Baltimore, MD; Washington University,
School of Medicine, St. Louis, MO; Vanderbilt-Ingram Cancer Center,
Nashville, TN; University of Wisconsin Comprehensive Cancer Center,
Madison ,WI; Cleveland Clinic Foundation, Cleveland, OH; University
of Pittsburgh, Pittsburgh, PA; Columbia-Presbyterian Medical Center,
New York, NY; Cancer Institute of New Jersey (CINJ), New Brunswick,
NJ; Oregon Health & Science University, Portland, OR. Adjuvant
weekly Docetaxel (D) for high-risk prostate cancer patients (pts)
after radical prostatectomy (RP): Preliminary data of a multicenter
pilot trial. Annual ASCO Meeting, p.417 (Abstract # 4649),
2004.
- Eisneberger M, Dewit R, Tannock I et al . A
comparison of Weekly or every 3 weeks Docetaxel vs Mitoxantrone
+ prednisone in patients with Hormone Refractory Prostate Cancer.
Annual ASCO meeting (Abstract #4) –Plenary presentation,2004.
- Rosenbaum E, Eisenberger MA. Survival Benefit
for Hormone Refractory Prostate
Cancer Patients Treated With Docetaxel: Commentary on tax 327. American
Journal of Urology Review, December 2004.
AUDIOVISUAL
- "Prostate Cancer" - Educational Section - Annual Meeting
of the American Society of Clinical Oncology, Los Angeles, 1986 (Cassettes)
"Prostate Cancer" - Educational Section - American Society
of Clinical Oncology, Orlando, Florida, 1993
-
A Prostate Cancer@ - Educational Section - American Society of Clinical
Oncology, Atlanta, GA, 1999
CME Instruction - See Significant Participation In National or International
Meetings
Lectures/Symposia) - Including CME Instruction.
|
 |
 |